Claims for Patent: 9,810,692

Summary for Patent: 9,810,692

Title:	Methods for predicting the sensitivity of a subject to immunotherapy
Abstract:	The present invention relates to a method of assessing, predicting or monitoring the sensitivity of a subject having a tumor or cancer to an immunotherapeutic molecule acting on the subject\'s T cells, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to the use of corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to an immunotherapeutic molecule acting on the subject\'s T cells typically comprises a step a) of determining, in a biological sample from said subject, the expression level of soluble CD25 (sCD25) and, when the expression level is determined, a step b) of comparing at least said expression level to a reference expression level, thereby assessing whether the subject having a tumor is responsive or resistant to the immunotherapeutic molecule.
Inventor(s):	Hannani; Dalil (Villejuif, FR), Zitvogel; Laurence (Paris, FR), Robert; Caroline (Fontenay-aux-Roses, FR), Chaput-Gras; Nathalie (Paris, FR)
Assignee:	INSTITUT GUSTAVE ROUSSY (Villejuif, FR)
Application Number:	14/438,275
Patent Claims:	1. An in vitro method of assessing the sensitivity of a subject having melanoma to an immunotherapeutic molecule acting on the subject's T cells for treating melanoma, which method comprises a step a) of determining, in a biological sample from said subject selected from a blood, a serum, a plasma sample or a derivative thereof, the respective basal expression levels of soluble CD25 (sCD25) and of lactic acid dehydrogenase (LDH), and, when the sCD25 and LDH expression levels are determined, a step b) of comparing said sCD25 and LDH basal levels of expression to sCD25 and LDH, respectively, thereby assessing whether the subject having a tumor is sensitive or resistant to the immunotherapeutic molecule, wherein the immunotherapeutic molecule is an anti-CTLA-4 antibody and: when the LDH reference expression level is about 500 IU, the step of assessing whether the subject having melanoma is sensitive or resistant to the immunotherapeutic molecule comprises: i) identifying the subject as having melanoma that is resistant to the immunotherapeutic molecule based on the sCD25 basal expression level being above the sCD25 reference expression level and/or the LDH basal expression level being above the LDH reference expression level of about 500 IU; or ii) identifying the subject as having melanoma that is sensitive to the immunotherapeutic molecule based on the sCD25 basal expression level being below the sCD25 reference expression level together with the LDH basal expression level being below the LDH reference expression level of about 500 IU; and iii) administering therapeutic doses of an anti-CTLA-4 antibody to the subject identified as having a melanoma that is sensitive to the immunotherapeutic molecule, or iv) administering therapeutic doses of an anti-CTLA-4 antibody in combination with therapeutic doses of a compensatory molecule selected from interleukin-2 (IL-2), interleukin-15 (IL-15), IL-2 superkine, sushi IL-15, radioimmunoconjugate of anti-CD25 and immunotoxin or a combination of the compensatory molecules to the subject identified as having a melanoma that is resistant to the immunotherapeutic molecule. 2. The method according to claim 1, wherein the sCD25 and LDH expression levels determined in step a) are the sCD25 and LDH basal expression levels in the subject, and wherein step b) further comprises comparing said sCD25 and LDH basal expression levels, used as reference expression levels, to sCD25 and LDH response expression levels in the subject determined after administration to said subject of the immunotherapeutic molecule. 3. The method according to claim 1, wherein the melanoma is a metastatic or an unresectable melanoma. 4. The method according to claim 2, wherein the method comprises a step a) of determining the sCD25 and LDH basal expression levels, in a biological sample of the subject having melanoma, before any administration to the subject of the immunotherapeutic molecule for treating the subject's melanoma, a step a') of determining, in a biological sample of the subject having melanoma, the respective sCD25 and LDH response expression levels after the administration to said subject of at least one therapeutic dose of the immunotherapeutic molecule for treating melanoma, and a step b) of comparing said sCD25 and LDH response expression levels to said sCD25 and LDH basal expression levels and to reference expression levels in a control population, a sCD25 response expression level identical to the sCD25 basal expression level or below the sCD25 reference expression level, together with a LDH basal expression level below the LDH basal expression level and reference expression level being indicative of the sensitivity of the subject to the immunotherapeutic molecule. 5. The method according to claim 2, wherein the method comprises a step a) of determining the sCD25 and LDH basal expression levels, in a biological sample of the subject having melanoma, before any administration to the subject of the immunotherapeutic molecule for treating the subject's melanoma, a step a') of determining, in a biological sample of the subject having a tumor, the respective sCD25 and LDH response expression levels after the administration to said subject of at least one therapeutic dose of the immunotherapeutic molecule for treating melanoma, and a step b) of comparing said sCD25 and LDH response expression levels to said sCD25 and LDH basal expression levels and to reference expression levels in a control population, a sCD25 response expression level above the sCD25 basal expression level or the reference expression level, together with a LDH basal expression level above the LDH basal expression level and reference expression level, being indicative of a resistance of the subject to the immunotherapeutic molecule. 6. The method according to claim 1, wherein the LDH reference expression level is about 500 IU and the sCD25 reference expression level is 1260 pg/ml, and wherein the step of assessing whether the subject having the tumor is sensitive or resistant to the immunotherapeutic molecule comprises: i) identifying the subject as having the tumor that is resistant to the immunotherapeutic molecule based on the sCD25 basal expression level being above the sCD25 reference expression level of 1260 pg/ml and/or the LDH basal expression level being above the LDH reference expression level of about 500 IU; or ii) identifying the subject as having the tumor that is sensitive to the immunotherapeutic molecule based on the sCD25 basal expression level being below the sCD25 reference expression level of 1260 pg/ml and the LDH basal expression level being below the LDH reference expression level of about 500 IU. 7. The method of claim 1, the method comprising administering therapeutic doses of an anti-CTLA-4 antibody to the subject identified as having a melanoma that is sensitive to the immunotherapeutic molecule. 8. The method of claim 7, wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab. 9. A method of treating a melanoma in a subject, the method comprising the steps of: a) determining, in a biological sample from said subject selected from a blood, a serum, a plasma sample or a derivative thereof, the basal expression levels for sCD25 and LDH; b) comparing said basal expression levels of sCD25 and LDH in the biological sample of the subject to reference expression levels for sCD25 and LDH; and c) treating a melanoma in the subject by administering to the subject: i) therapeutic doses of an anti-CTLA-4 antibody alone when the basal expression level of sCD25 in the biological sample of the subject is below the reference expression level for sCD25 of 1260 pg/ml and the basal expression level of LDH in the biological sample of the subject is below the reference expression level for LDH of about 500 IU, or ii) therapeutic doses of an anti-CTLA-4 antibody in combination with therapeutic doses of a compensatory molecule selected from interleukin-2 (IL-2), interleukin-15 (IL-15), IL-2 superkine, sushi IL-15, radioimmunoconjugate of anti-CD25 and immunotoxin or a combination of the compensatory molecules when the expression level of sCD25 in the biological sample of the subject is above the reference expression level for sCD25 of 1260 pg/ml and/or the expression level of LDH in the biological sample of the subject is above the reference expression level for LDH of about 500 IU. 10. The method of claim 9, wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab. 11. The method of claim 1, said method comprising administering therapeutic doses of an anti-CTLA-4 antibody in combination with therapeutic doses of a compensatory molecule selected from interleukin-2 (IL-2), interleukin-15 (IL-15), IL-2 superkine, sushi IL-15, radioimmunoconjugate of anti-CD25 and immunotoxin or a combination of the compensatory molecules to the subject identified as having a melanoma that is resistant to the immunotherapeutic molecule. 12. The method of claim 7, wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab.

Details for Patent 9,810,692

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2032-10-26